Hope for patients in need

ZB131 is a monoclonal antibody that binds to cancer cells with cancer-specific plectin (CSP) on their surface, inducing a form of programmed cell death. For more information about monoclonal antibody treatments for cancer, click here.

This study is for people who meet the following eligibility criteria:

• Have advanced or metastatic pancreatic, ovarian, or bile duct cancer
• Are 18 years of age or older
• Have failed all available therapies or are ineligible for standard of care treatment

Your doctor or healthcare provider can help determine if you may be a good fit for the ZB131 clinical trial. For a complete list of eligibility criteria, see ClinicalTrials.gov.

• Potential participants will start with a screening visit to confirm their eligibility for the study. The staff at the trial site will take patients’ medical history and perform a physical exam to ensure they meet the study requirements.
• ZB131 will be administered via IV every week at one of our trial sites.
• During study visits, participants will undergo tests and procedures in addition to those that are part of regular care for their type of cancer to study the treatment’s effect.